gsk peptide has been researched along with Waldenstrom Macroglobulinemia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, KC; Azab, AK; Azab, F; Chuma, S; Ghobrial, IM; Harris, B; Hong, F; Jia, X; Leduc, R; Leleu, X; Richardson, PG; Roccaro, A; Rodig, S; Rourke, M; Rubin, N; Sacco, A; Sportelli, P; Varticovski, L; Warren, D; Weller, E | 1 |
1 trial(s) available for gsk peptide and Waldenstrom Macroglobulinemia
| Article | Year |
|---|---|
Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Oligopeptides; Phosphorylcholine; Prognosis; Proto-Oncogene Proteins c-akt; Recurrence; Waldenstrom Macroglobulinemia | 2010 |